Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|14|2090-2098

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.14, 2014-07, pp. : 2090-2098

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation

By  

Oncology, Vol. 87, Iss. 4, 2014-07 ,pp. : 215-223

Karger

Access to resources Recommend Favorite

Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung

By  

Oncology Research and Treatment, Vol. 39, Iss. 7-8, 2016-06 ,pp. : 461-463

Karger

Access to resources Recommend Favorite

Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations

By  

Oncology, Vol. 89, Iss. 5, 2015-0 ,pp. : 275-280

Karger

Access to resources Recommend Favorite

Discrepancy between the Clinical Image and Pathological Findings of Non-Small Cell Lung Cancer Harboring an Epidermal Growth Factor Receptor Gene Mutation That Was Surgically Resected after Gefitinib Treatment

By  

Case Reports in Oncology, Vol. 7, Iss. 1, 2014-02 ,pp. : 126-131

Karger

Access to resources Recommend Favorite

Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I–IV Non-Small Cell Lung Cancer Patients

By  

Respiration, Vol. 85, Iss. 2, 2012-07 ,pp. : 119-125

Karger

Access to resources Recommend Favorite